October 22, 2024

The S&P 500 and the Dow Jones Industrial Average finished Tuesday marginally lower, as investors grappled with ongoing concerns about a potential rise in interest rates and processed this week’s latest earnings reports. The S&P 500 closed down 0.05 per cent, finishing at 5,851.20. This marked the broad market index’s first consecutive loss since early […]

Over the past year, the price of gold has experienced something unusual. It has reached record highs, seemingly disconnected from traditional influencers like interest rates, inflation, and the dollar. Even more striking is its steady ascent, which stands in contrast to the volatility of major geopolitical events. Gold’s status as a “safe-haven” asset has evolved,

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses investing mistakes. Key pointsMany of the mistakes investors make are based on common sense rules of thumb that turn out to be wrong.As a result, it’s often wise for investors to turn common sense logic on its head.The easiest way to avoid

Immutep (ASX:IMM) has released its annual report, detailing significant progress over the past year with its lead immunotherapy candidate eftilagimod alpha (efti). This drug is designed to activate the body’s immune system to better recognise and attack cancer cells. It targets LAG-3, a protein that plays a key role in regulating immune responses. Specifically, efti

Australian semiconductor company BluGlass (ASX:BLG) has entered into a promising multi-phase Joint Development Agreement (JDA) with Uviquity, a US-based venture-backed start-up. The first phase of this agreement, valued at A$1.2 million, involves the development of advanced photonic chips. This collaboration aims to integrate BluGlass’ expertise in gallium nitride (GaN) laser technology with Uviquity’s innovations in

Medical technology company ImpediMed (ASX:IPD) continues to make strides with its SOZO® Digital Health Platform, reporting significant progress in its Q1 FY25 results. The company’s pipeline for SOZO units increased by 34%, with 28 units sold in the US, a notable rise from the previous quarter’s 23 units. SOZO, which uses bioimpedance spectroscopy (BIS), is

Next Science Limited (ASX:NXS), a Sydney-based medical technology company, has reported a 7% dip in product sales for the third quarter of FY24, generating US$4.7 million. The decline follows the restructuring of its Durable Medical Equipment (DME) sales channel. Despite these challenges, the company remains optimistic about future growth, with total year-to-date sales up 5%.

Praemium Limited (ASX:PPS) reported a robust start to FY25, with total Funds Under Administration (FUA) increasing by 33% to $59.4 billion as of 30 September 2024, outpacing market expectations. This included a 30% jump in platform FUA to $29.0 billion. Praemium’s Separately Managed Accounts (SMA) continued to be a key driver, contributing $11.9 billion of

Transurban (ASX:TCL) reported a 1.1% rise in average daily traffic (ADT) for the September 2024 quarter, reaching 2.5 million daily trips across its assets. While Sydney and Brisbane saw increases of 1.9% and 1.3%, respectively, Melbourne experienced a 1% decline due to ongoing construction projects such as the West Gate Tunnel and lower container volumes

Mirvac Group (ASX:MGR) has made a strong start to FY25, driven by its residential and industrial segments and a $0.5 billion non-core asset sales program. In its Q1 FY25 operational update, Mirvac confirmed it finalised the sale of its Melbourne property at 367 Collins Street and entered into a $50 million deal for the sale